1,3-二甲基-5-吗啉-1H-吡唑-4-胺 | 568577-87-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,3-二甲基-5-吗啉-1H-吡唑-4-胺
• 英文名称: 1,3-dimethyl-5-morpholino-1H-pyrazol-4-amine
• 英文别名: 1,3-dimethyl-5-morpholin-4-ylpyrazol-4-amine
• CAS: 568577-87-7
• 化学式: C₉H₁₆N₄O
• 分子量: 196.252
• InChiKey: LEVZXNJICHTQEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	1 3-Dimethyl-5-morpholino-1H-pyrazol-4-amine Material Safety Data Sheet
Synonym:	None Known
CAS:	568577-87-7

Section 1 - Chemical Product MSDS Name:1 3-Dimethyl-5-morpholino-1H-pyrazol-4-amine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
568577-87-7	1,3-Dimethyl-5-morpholino-1H-pyrazol-4	97+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 568577-87-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 155.5-156.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H16N4O
Molecular Weight: 196.25

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 568577-87-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3-Dimethyl-5-morpholino-1H-pyrazol-4-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 568577-87-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 568577-87-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 568577-87-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二甲基-5-吗啉-1H-吡唑-4-胺 、 4-甲氧基-2,3,6-三甲基苯磺酰氯 在 吡啶 作用下， 以62%的产率得到N-(1,3-dimethyl-5-morpholino-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
  参考文献：
  名称：

  Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

  摘要：

  N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.

  DOI：

  10.1021/jm201091t

文献信息

• Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis
  作者：Oscar Mammoliti、Adeline Palisse、Caroline Joannesse、Sandy El Bkassiny、Brigitte Allart、Alex Jaunet、Christel Menet、Beatrice Coornaert、Kathleen Sonck、Inge Duys、Philippe Clément-Lacroix、Line Oste、Monica Borgonovi、Emanuelle Wakselman、Thierry Christophe、Nicolas Houvenaghel、Mia Jans、Bertrand Heckmann、Laurent Sanière、Reginald Brys

  DOI：10.1021/acs.jmedchem.1c00138

  日期：2021.5.13

  that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold

  越来越多的文献表明，阻断S1P2受体（S1PR2）信号传导可能有效治疗特发性肺纤维化（IPF）。然而，到目前为止，仅公开了几种拮抗剂。化学促成策略导致发现具有良好拮抗剂活性的吡啶系列。通过支架跳跃鉴定了具有改善的亲脂性效率并且没有CYP抑制责任的哒嗪系列。进一步的优化导致了40（GLPG2938）的发现，该化合物对表型IL8释放测定具有出色的功效，在博莱霉素诱导的肺纤维化模型中具有良好的药代动力学和良好的活性。
• GANGLIOSIDE GD2 AS A MARKER AND TARGET ON CANCER STEM CELLS
  申请人：Board of Regents , The University of Texas System

  公开号：US20150044233A1

  公开（公告）日：2015-02-12

  Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.
• US9846160B2
  申请人：——

  公开号：US9846160B2

  公开（公告）日：2017-12-19
• [EN] N-MYRISTOYL TRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE N-MYRISTOYL-TRANSFÉRASE
  申请人：UNIV DUNDEE

  公开号：WO2010026365A1

  公开（公告）日：2010-03-11

  The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.
• [EN] GANGLIOSIDE GD2 AS A MARKER AND TARGET ON CANCER STEM CELLS<br/>[FR] GANGLIOSIDE GD2 EN TANT QUE MARQUEUR ET CIBLE SUR DES CELLULES SOUCHES CANCÉREUSES
  申请人：UNIV TEXAS

  公开号：WO2013130603A1

  公开（公告）日：2013-09-06

  Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.